Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | YAP1 | P46937 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HRH2 | P25021 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL865847 | 1.00 | GPR119 (0.45) | GPR119ALDH1A1LMNAYAP1KMT2A | |
| SCHEMBL1722091 | 0.94 | HRH2 (0.42) | GPR119ALDH1A1LMNAYAP1KMT2A | |
| SCHEMBL865013 | 0.93 | GPR119 (0.44) | GPR119ALDH1A1LMNAYAP1KMT2A | |
| SCHEMBL865831 | 0.92 | GPR119 (0.57) | GPR119 | |
| SCHEMBL865832 | 0.92 | GPR119 (0.57) | GPR119 | |
| SCHEMBL864520 | 0.90 | GPR119 (0.42) | GPR119ALDH1A1LMNAKMT2AMAPK1 | |
| SCHEMBL864521 | 0.90 | GPR119 (0.42) | GPR119ALDH1A1LMNAKMT2AMAPK1 | |
| SCHEMBL10101193 | 0.90 | ALDH1A1 (0.41) | GPR119ALDH1A1LMNAKMT2AHRH2 | |
| SCHEMBL865185 | 0.90 | ALDH1A1 (0.41) | GPR119ALDH1A1LMNAKMT2AHRH2 | |
| SCHEMBL865184 | 0.90 | ALDH1A1 (0.41) | GPR119ALDH1A1LMNAKMT2AHRH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120077793-A1 | Compounds for the Treatment of Metabolic Disorders | PROSIDION LIMITED (GB) | 2012-03-29 | — | — | US | disclosed |
| EP-2406247-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | Prosidion Limited (GB) | 2012-01-18 | — | — | EP | disclosed |
| WO-2010103333-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2010-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077793-A1 | Compounds for the Treatment of Metabolic Disorders | GPR119, GPR132, FFAR2 | GPR119 1/4885ALDH1A1 1300/4885LMNA 4011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.